19:48 , Sep 8, 2017 |  BC Week In Review  |  Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...
00:59 , Sep 8, 2017 |  BC Extra  |  Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...
21:04 , Nov 11, 2016 |  BC Week In Review  |  Company News

Eli Lilly, Eddingpharm deal

Eli Lilly granted Eddingpharm exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly said the deal will enable it to focus resources on its...
00:03 , Nov 11, 2016 |  BC Extra  |  Company News

Lilly grants Eddingpharm antibiotic rights in China

Eli Lilly and Co. (NYSE:LLY) granted Eddingpharm Inc. (Shanghai, China) exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly spokesperson Teresa Shewman declined to...
08:00 , Jan 17, 2005 |  BioCentury  |  Regulation

Timing losses in stock fraud

Although predicting a Supreme Court decision based on oral arguments is a risky proposition, skeptical comments made by several justices last week suggest the court is inclined to reverse a decision that lowered the bar...
08:00 , Nov 3, 2003 |  BioCentury  |  Strategy

Ranbaxy's top sellers

Ranbaxy's top sellers...
08:00 , Nov 10, 2000 |  BC Extra  |  Company News

Elan completes acquisition of Dura

ELN completed its acquisition of DURA (see BioCentury, Sept. 18). DURA shareholders will receive 0.6715 of an ELN ADS for each DURA share held. ELN said the transaction will be accretive to its earnings in...
07:00 , Sep 18, 2000 |  BC Week In Review  |  Company News

Dura, Elan deal

ELN will acquire DURA in a stock transaction. DURA shareholders will receive 0.6715 ELN ADSs for each DURA share. Based on ELN's closing stock price of $52.125 on Sept. 8, the deal values DURA at...
07:00 , Sep 11, 2000 |  BC Extra  |  Top Story

Top tiers in takeovers

M&A activity picked up on Monday with a fury with three top tier biotech companies, Elan (ELN), Genzyme General (GENZ) and Human Genome Sciences (HGSI), announcing deals totaling nearly $3 billion. ELN entered a definitive...
07:00 , May 3, 1999 |  BioCentury  |  Strategy

Dura trying to extend its model

Dura trying to extend its model Dura Pharmaceuticals Inc. was one of the darlings of Wall Street in 1997, with its strategy of in-licensing and acquisition to build complementary respiratory product lines. But the company...